Peringatan Keamanan

LD50 is 15800 mg/kg (orally in rats).

Sulfapyridine

DB00891

small molecule approved

Deskripsi

Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.

Struktur Molekul 2D

Berat 249.289
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 6-14 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Approximately 60-80%

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

335 Data
Nicotine The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Nicotine.
Mecamylamine The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine.
Pentolinium The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Trimethaphan.
Hexamethonium The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Hexamethonium.
Cyclopentamine The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Cyclopentamine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Sulfapyridine is combined with Prilocaine.
Methotrexate The protein binding of Methotrexate can be increased when combined with Sulfapyridine.
Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine.
Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Sulfapyridine.
Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfapyridine.
Cyclosporine The risk or severity of renal failure can be increased when Sulfapyridine is combined with Cyclosporine.
Insulin human The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin human.
Insulin lispro The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin lispro.
Insulin glargine The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin glargine.
Insulin pork The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin pork.
Troglitazone The metabolism of Troglitazone can be decreased when combined with Sulfapyridine.
Glimepiride The metabolism of Glimepiride can be decreased when combined with Sulfapyridine.
Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Sulfapyridine.
Disopyramide The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfapyridine.
Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Sulfapyridine.
Metformin The therapeutic efficacy of Metformin can be increased when used in combination with Sulfapyridine.
Rosiglitazone The metabolism of Rosiglitazone can be decreased when combined with Sulfapyridine.
Acetohexamide The metabolism of Acetohexamide can be decreased when combined with Sulfapyridine.
Miglitol The therapeutic efficacy of Miglitol can be increased when used in combination with Sulfapyridine.
Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Sulfapyridine.
Nateglinide The metabolism of Nateglinide can be decreased when combined with Sulfapyridine.
Pentamidine The therapeutic efficacy of Pentamidine can be increased when used in combination with Sulfapyridine.
Mifepristone The therapeutic efficacy of Mifepristone can be increased when used in combination with Sulfapyridine.
Tolazamide The metabolism of Tolazamide can be decreased when combined with Sulfapyridine.
Repaglinide The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfapyridine.
Phenformin The therapeutic efficacy of Phenformin can be increased when used in combination with Sulfapyridine.
Glyburide The metabolism of Glyburide can be decreased when combined with Sulfapyridine.
Glipizide The metabolism of Glipizide can be decreased when combined with Sulfapyridine.
Gliclazide The metabolism of Gliclazide can be decreased when combined with Sulfapyridine.
Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Sulfapyridine.
Pioglitazone The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfapyridine.
Bromocriptine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfapyridine.
Gliquidone The metabolism of Gliquidone can be decreased when combined with Sulfapyridine.
Mitiglinide The therapeutic efficacy of Mitiglinide can be increased when used in combination with Sulfapyridine.
Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Sulfapyridine.
Sunitinib The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfapyridine.
Exenatide The therapeutic efficacy of Exenatide can be increased when used in combination with Sulfapyridine.
Mecasermin The therapeutic efficacy of Mecasermin can be increased when used in combination with Sulfapyridine.
Pramlintide The therapeutic efficacy of Pramlintide can be increased when used in combination with Sulfapyridine.
Glisoxepide The metabolism of Glisoxepide can be decreased when combined with Sulfapyridine.
Insulin aspart The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin aspart.
Insulin detemir The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin detemir.
Insulin glulisine The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin glulisine.
Glymidine The therapeutic efficacy of Glymidine can be increased when used in combination with Sulfapyridine.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Sulfapyridine.
Buformin The therapeutic efficacy of Buformin can be increased when used in combination with Sulfapyridine.
Vildagliptin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfapyridine.
Voglibose The therapeutic efficacy of Voglibose can be increased when used in combination with Sulfapyridine.
NN344 The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with NN344.
AMG-222 The therapeutic efficacy of AMG-222 can be increased when used in combination with Sulfapyridine.
Bisegliptin The therapeutic efficacy of Bisegliptin can be increased when used in combination with Sulfapyridine.
Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfapyridine.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfapyridine.
Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Sulfapyridine.
Liraglutide The therapeutic efficacy of Liraglutide can be increased when used in combination with Sulfapyridine.
Gosogliptin The therapeutic efficacy of Gosogliptin can be increased when used in combination with Sulfapyridine.
Linagliptin The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfapyridine.
Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfapyridine.
Glibornuride The metabolism of Glibornuride can be decreased when combined with Sulfapyridine.
Benfluorex The therapeutic efficacy of Benfluorex can be increased when used in combination with Sulfapyridine.
Empagliflozin The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfapyridine.
Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfapyridine.
Dulaglutide The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sulfapyridine.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Sulfapyridine.
Netoglitazone The therapeutic efficacy of Netoglitazone can be increased when used in combination with Sulfapyridine.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Sulfapyridine.
Ciglitazone The therapeutic efficacy of Ciglitazone can be increased when used in combination with Sulfapyridine.
Lixisenatide The therapeutic efficacy of Lixisenatide can be increased when used in combination with Sulfapyridine.
Insulin beef The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin beef.
Insulin degludec The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin degludec.
Insulin peglispro The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hypoglycemia can be increased when Sulfapyridine is combined with Insulin tregopil.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Sulfapyridine.
Dutogliptin The therapeutic efficacy of Dutogliptin can be increased when used in combination with Sulfapyridine.
Allicin The therapeutic efficacy of Allicin can be increased when used in combination with Sulfapyridine.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Sulfapyridine.
Ertugliflozin The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Sulfapyridine.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Sulfapyridine.
Teneligliptin The therapeutic efficacy of Teneligliptin can be increased when used in combination with Sulfapyridine.
Omarigliptin The therapeutic efficacy of Omarigliptin can be increased when used in combination with Sulfapyridine.
Carmegliptin The therapeutic efficacy of Carmegliptin can be increased when used in combination with Sulfapyridine.
Gemigliptin The therapeutic efficacy of Gemigliptin can be increased when used in combination with Sulfapyridine.
Anagliptin The therapeutic efficacy of Anagliptin can be increased when used in combination with Sulfapyridine.
Evogliptin The therapeutic efficacy of Evogliptin can be increased when used in combination with Sulfapyridine.
Sotagliflozin The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Sulfapyridine.
Balaglitazone The therapeutic efficacy of Balaglitazone can be increased when used in combination with Sulfapyridine.
Remogliflozin etabonate The therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Sulfapyridine.
Carbutamide The metabolism of Carbutamide can be decreased when combined with Sulfapyridine.
Guar gum The therapeutic efficacy of Guar gum can be increased when used in combination with Sulfapyridine.
Metahexamide The metabolism of Metahexamide can be decreased when combined with Sulfapyridine.
Semaglutide The therapeutic efficacy of Semaglutide can be increased when used in combination with Sulfapyridine.
Taspoglutide The therapeutic efficacy of Taspoglutide can be increased when used in combination with Sulfapyridine.
Englitazone The therapeutic efficacy of Englitazone can be increased when used in combination with Sulfapyridine.
Tirzepatide The therapeutic efficacy of Tirzepatide can be increased when used in combination with Sulfapyridine.

Target Protein

Dihydropteroate synthase folP
Dihydropteroate synthase type-1 sulI

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Dagenan Tab 500mg
    Tablet • 500 mg • Oral • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul